Business
Liquidia Announces Poster Presentations at the American Thoracic Society (ATS) 2025 International Conference
- Data from the ASCENT study of LIQ861 (YUTREPIA™) in PH-ILD patients highlights safety, tolerability, exploratory changes in six-minute walk distance,
About this update from Liquidia Corporation
[{"type":"text","content":"- Data from the ASCENT study of LIQ861 (YUTREPIA™) in PH-ILD patients highlights safety, tolerability, exploratory changes in six-minute walk distance, cardiac effort and quality of life - Case study highlights the long-term safety and tolerability of LIQ861 (YUTREPIA) in a PAH patient transitioning from parenteral treprostinil in INSPIRE study MORRISVILLE, N.C., March 27, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced the company will present three posters at the American Thoracic Society (ATS) 2025 International Conference, taking place May 18-21, 2025, in San Francisco. Two posters will highlight new data from the company’s open-label ASCENT study of LIQ861 (YUTREPIA) in PH-ILD patients with a focus on safety, tolerability, exploratory changes in 6-minute walk distance, quality of life, and changes in cardiac effort. A third poster is a case study of a patient with PAH participating in the open-label extension study (INSPIRE). Poster Discussion Session: Poster Board #1404Date and time: Tuesday, May 20, 2025 from 11:30 a.m. – 1:15 p.m. PTPresenting Author: Rajan Saggar, MDAbstract: An ASCENT to Week 8: Initial Safety and Exploratory Efficacy Data on LIQ861 Dry Powder Inhaled Treprostinil in PH-ILD Patients Poster Discussion Session: Poster Board #1401Date and time: Tuesday, May 20, 2025 from 11:30 a.m. – 1:15 p.m. PTPresenting Author: Daniel Lachant, MDAbstract: Changes in Cardiac Effort in Pulmonary Hypertension-Interstitial Lung Disease: Insights From the ASCENT Trial Poster Discussion Session: Poster Board #1464Date and time: Tuesday, May 20, 2025 from 11:30 a.m. – 1:15 p.m. PTPresenting Author: Rodolfo Estrada, MDAbstract: Transitioning From Parenteral Treprostinil to LIQ861 in a Patient With PAH Following the presentations, each poster will be available on the Publications page of Liquidia’s website at https://liquidia.com/publications. About YUTREPIA™ (treprostinil) Inhalation Powder YUTREPIA is an investigational, inhaled dry-powder formulation of treprostinil delivered through a convenient, low-effort, palm-sized device. In August 2024, the FDA issued tentative approval of YUTREPIA for the PAH and PH-ILD indications. YUTREPIA was designed using Liquidia’s PRINT® technology, which en...